

Press Release

Cellzome Announces Achievement of Fourth Milestone in Inflammation Alliance with GlaxoSmithKline

Cambridge, United Kingdom and Heidelberg, Germany, 30th September 2009: Cellzome Inc. announced today that it has successfully achieved the fourth milestone in its strategic alliance with GlaxoSmithKline. The achievement of this milestone triggers a further payment from GlaxoSmithKline. The amounts of these payments are undisclosed.

In September 2008, Cellzome and GlaxoSmithKline announced the signing of a worldwide strategic alliance which uses Cellzome's drug discovery and development capabilities and its proprietary *Kinobeads*[™] technology to identify, develop and market novel, kinase-targeted therapeutics to treat inflammatory diseases. GSK has exclusive options to license drug candidates from Cellzome's kinase programs directed against seven targets. Cellzome will develop these programs to clinical proof of concept, unless GSK elects to exercise its option earlier. Cellzome is eligible to receive success-based milestones from GSK as product candidates are advanced. Earlier milestones in the alliance were announced in December 2008 and March 2009.

Tim Edwards, CEO of Cellzome, said: "We continue to make excellent progress in our collaboration with GSK. Both teams are aligned and working very well together."

- ends -

For more information please contact:

Cellzome:

Tim Edwards
Chief Executive Officer
Tel: +49 (0) 6221-137 57-100
press@cellzome.com

Media contact:

Hogarth Partnership
Sarah MacLeod
Tel: +44 (0) 207 357 9477

About Cellzome Inc.

Cellzome is a privately-owned drug discovery and development company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by *Kinobeads*[™], a proprietary technology for the screening and profiling of kinase inhibitors in physiologically-relevant cells and tissues. The most advanced program, targeting PI3K γ , is anticipated to enter the clinic in 2010, and several other programs are in early preclinical testing.

Cellzome is expanding its distinctive technology, in a novel form called *Episphere*[™], to the discovery and development of novel drug candidates for epigenetic targets in their protein complexes.

Cellzome has significant collaborations with GSK and Johnson & Johnson. Its holding company is domiciled in the US and it employs about 90 people at its two laboratories in Cambridge, UK and Heidelberg, Germany.